Format

Send to

Choose Destination
Eur J Clin Microbiol Infect Dis. 1997 Oct;16(10):767-9.

In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.

Author information

1
Clinical Microbiology Institute, Wilsonville, Oregon 97070, USA.

Abstract

The purpose of this study was to compare the in vitro activity of a new ketolide, HMR 3004 (RU64004), to that of three macrolides and one azalide against 608 Streptococcus pneumoniae and 202 Haemophilus influenzae. Macrolide-resistant pneumococci were susceptible to HMR 3004, even if they were resistant to clindamycin. Against Haemophilus influenzae, HMR 3004 and azithromycin were nearly identical in potency; the macrolides were 8- to 16-fold less active. HMR 3004 may be useful for treating respiratory tract infections if sufficient concentrations can be achieved at the local sites of infection.

PMID:
9405952
DOI:
10.1007/bf01709263
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center